NASDAQ:OTICOtonomy Stock Price, Forecast & News

Otonomy's stock was trading at $2.62 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, OTIC stock has decreased by 2.3% and is now trading at $2.56. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Otonomy in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Otonomy.

Otonomy is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Otonomy.

Otonomy Inc (NASDAQ:OTIC) issued its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by $0.02. The biopharmaceutical company had revenue of $0.16 million for the quarter. Otonomy had a negative return on equity of 98.90% and a negative net margin of 7,826.41%. View Otonomy's earnings history.

3 brokerages have issued 12 month target prices for Otonomy's shares. Their forecasts range from $8.00 to $8.00. On average, they anticipate Otonomy's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 212.5% from the stock's current price. View analysts' price targets for Otonomy.

Media stories about OTIC stock have been trending negative recently, InfoTrie reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Otonomy earned a news impact score of -2.8 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutOtonomy.

Otonomy saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 137,800 shares, a decrease of 14.1% from the April 30th total of 160,400 shares. Based on an average daily trading volume, of 134,900 shares, the short-interest ratio is currently 1.0 days. Currently, 0.6% of the shares of the stock are short sold. View Otonomy's Current Options Chain.

Some companies that are related to Otonomy include Selecta Biosciences (SELB), Bicycle Therapeutics (BCYC), Avid Bioservices (CDMO), TherapeuticsMD (TXMD), MannKind (MNKD), Verrica Pharmaceuticals (VRCA), Osmotica Pharmaceuticals (OSMT), Concert Pharmaceuticals (CNCE), Lannett (LCI), Avadel Pharmaceuticals (AVDL), Urovant Sciences (UROV), Ovid Therapeutics (OVID), Verastem (VSTM), Neptune Wellness Solutions (NEPT) and ProQR Therapeutics (PRQR). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Otonomy investors own include Canaccord Genuity (), BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird () and Wellington Shields ().

Otonomy trades on the NASDAQ under the ticker symbol "OTIC."

Otonomy's stock is owned by a number of institutional and retail investors. Top institutional investors include First Manhattan Co. (3.26%), BlackRock Inc. (2.58%), Granahan Investment Management Inc. MA (0.54%), Acadian Asset Management LLC (0.52%), Mercer Global Advisors Inc. ADV (0.29%) and Orbimed Advisors LLC (0.23%). View institutional ownership trends for Otonomy.

OTIC stock was sold by a variety of institutional investors in the last quarter, including First Manhattan Co., Orbimed Advisors LLC, Mercer Global Advisors Inc. ADV, and BlackRock Inc.. View insider buying and selling activity for Otonomy.

OTIC stock was bought by a variety of institutional investors in the last quarter, including Granahan Investment Management Inc. MA, Acadian Asset Management LLC, Connor Clark & Lunn Investment Management Ltd., Ensign Peak Advisors Inc, and JPMorgan Chase & Co.. View insider buying and selling activity for Otonomy.

Shares of OTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of OTIC stock can currently be purchased for approximately $2.56.

Otonomy has a market capitalization of $79.03 million and generates $600,000.00 in revenue each year. The biopharmaceutical company earns $-44,670,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis. Otonomy employs 49 workers across the globe.

The official website for Otonomy is www.otonomy.com.

Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 619-323-2200 or via email at [email protected]